MLB Announces IND Approval by US FDA to Initiate Phase 1 Trial of TML-6, a New Era Multi-Target Drug for the Treatment of Alzheimer’s Disease

TAINAN, June 7, 2024 /PRNewswire/ — MLB (Merry Life Biomedical Company, Ltd., Taiwan: https://www.tmlbio.com/), a biomedical company, announced that the U.S. Food and Drug Administration (FDA) has approved IND application for TML-6, an novel drug to treat Alzheimer’s disease (AD),…